Why European Supplement Brands Get Their Health Canada NPN Application Rejected — And What to Fix Before You Apply

Health Canada has licensed over 55,000 natural health products in Canada since the NHP Regulations (SOR/2003-196) came into force on 1 January 2004. The framework was designed to balance consumer access with safety and efficacy requirements — a sensible goal. But for European supplement manufacturers entering the Canadian market for the first time, it functions as a series of technical traps. Dossiers built on EFSA scientific opinions come back from the Natural Health Products Directorate (NHPD) with a Notice of Deficiency. Labels compliant with EU Regulation (EC) No 1924/2006 on nutrition and health claims fail Canadian labelling requirements. And products that have sold freely across Europe for two decades can’t clear Health Canada’s site licence requirement before a single substantive review even begins.

We see this pattern regularly. A well-resourced European manufacturer — GMP-certified, documented, audit-ready — submits an NPN application and waits. Months later, they receive a Notice of Deficiency listing anywhere from 6 to 14 distinct deficiencies, most of which could have been identified and resolved before submission. The review clock resets, the process restarts, and timelines for non-compendial applications commonly extend beyond 3 years.

The frustrating truth is that most of these rejections are preventable. The failure points are consistent, they’re well-documented, and they cluster around a handful of structural mismatches between the EU and Canadian regulatory frameworks. Here’s what’s actually going wrong — and what to do about it before you file.

Why the Canadian NHP Framework Is Nothing Like the EU System

The comparison that catches European brands out most often is the perceived similarity between EFSA and NHPD. Both evaluate safety and efficacy for products making health-related claims. But that surface resemblance obscures a fundamentally different architecture.

In the EU, health claims are centrally authorized. A claim either appears on the EU Register of authorised nutrition and health claims under Articles 13 or 14 of Regulation (EC) No 1924/2006 — or it doesn’t. The evidentiary work is already done at the EU level. You use the authorized claim language, comply with the conditions of use attached to the authorization, and your product is largely compliant from a claims perspective.

In Canada, every product requires an individual product licence application. There is no central pre-authorization of claims that applies automatically to your product. Instead, NHPD reviews each application against its own evidence framework. For products that match an NHPD-published product monograph — Health Canada has published several hundred covering specific ingredient-claim combinations — you can submit a compendial application using that monograph’s pre-cleared evidence. Compendial applications are faster and more predictable, typically processing within 10 to 60 days once complete.

For products that don’t fit an existing monograph, you submit a non-compendial application and provide your own clinical evidence. Those applications can take anywhere from 18 months to over 3 years. And the evidence standard they require is not the same as the standard EFSA applies. Submitting an EFSA-built dossier without adaptation almost always generates a Notice of Deficiency on the evidence section alone.

One more structural point: Canada is a bilingual country with two official languages under the Official Languages Act. That has direct regulatory consequences for NHP labelling that we’ll return to below.

Rejection Reason 1: Your Evidence Is Built on European Logic

This is the most common source of deficiencies in European submissions, and it comes in several distinct forms.

First, pharmacopoeial references. European brands instinctively use Ph.Eur. (European Pharmacopoeia) monographs to establish ingredient quality specifications. Health Canada recognizes Ph.Eur. — but only alongside USP (United States Pharmacopeia) and BP (British Pharmacopoeia). Where NHPD’s own Compendium of Monographs includes an entry for your ingredient, that listing takes precedence. Submitting a Ph.Eur. reference without addressing NHPD Compendium specifications for a compendially-covered ingredient generates a quality deficiency almost automatically.

Second, traditional use evidence. Health Canada’s standard for traditional use claims is specific: you need written historical evidence of use spanning at least 150 years, with a minimum of 50 continuous years within the referenced traditional medicine system. ESCOP (European Scientific Cooperative on Phytotherapy) monographs and EMA community herbal monographs are acceptable reference materials in principle — but only where the evidence maps precisely to the form, dose, preparation, and indication you’re claiming. Partial overlap doesn’t satisfy the standard. European brands frequently cite ESCOP monographs for a standardized extract when the monograph documents use of a traditional infusion. Health Canada flags the mismatch.

Third, for non-traditional (modern) claims, NHPD expects human clinical evidence directly supporting your proposed claim at your proposed dose. This means randomized controlled trials, systematic reviews, or meta-analyses. Preclinical studies and in vitro data can provide supporting context, but they cannot carry a non-traditional claim on their own. Many European brands include mechanistic or preclinical evidence as primary support — it isn’t.

Rejection Reason 2: Your Label Was Written for a European Audience

Part 5 of the NHP Regulations governs labelling requirements in detail, and it contains two categories of requirement that consistently trip up European applicants: mandatory content fields and bilingualism.

The bilingual requirement is absolute. Under Canada’s Official Languages Act and the NHP Regulations, every NHP sold in Canada must carry full required information in both English and French. Not a translated sticker applied after the fact — full bilingual labelling integrated into the primary and secondary panels in accordance with NHPD’s bilingual labelling guidance. European brands producing labels for single-language markets (including French brands producing French-only labels) don’t have bilingual labelling by default, and this generates an immediate deficiency.

Beyond bilingualism, the mandatory label fields must match your approved product licence exactly. Required elements include:

• The product name as approved in your product licence
• Your NPN or DIN-HM number, displayed as required once issued
• All medicinal ingredients listed with quantity per dosage unit and, for botanicals, the source organism identified by proper Latin binomial nomenclature (genus and species, with the plant part specified)
• Recommended use or purpose — using the exact wording from your approved application, not paraphrased equivalents
• Recommended dose: quantity, route of administration, frequency, and duration of use
• All cautions, warnings, and contraindications required by the applicable product monograph or by NHPD reviewers during assessment

That last point is one where European brands consistently underestimate NHPD’s rigour. If your product monograph specifies a mandatory caution — for example, “Consult a healthcare practitioner prior to use if you are pregnant or breastfeeding” — that caution must appear verbatim. It cannot be paraphrased, shortened, or merged with other label text. EU-style cautionary language, even where functionally equivalent, will be flagged as non-compliant.

Rejection Reason 3: No Site Licence Means No Product Licence

This is the requirement that stops applications before they start, and many European brands discover it only after they’ve invested several months of dossier preparation.

Under Division 2 of the NHP Regulations, every facility that manufactures, packages, labels, imports, or distributes NHPs in Canada must hold a valid site licence. The site licence is product-independent — it’s issued to a facility, not to a product. It requires demonstrated compliance with the GMP standards set out in the NHP Regulations, which are roughly aligned with ISO 22716 for cosmetic-adjacent products but include specific Canadian documentation, batch release, and stability testing expectations.

For European brands without a Canadian legal entity, the practical consequence is straightforward: you need a licensed Canadian partner — a contract manufacturer, a licensed importer, or a third-party site licence holder willing to be named on your product licence — before your application is administratively complete. An application that names an unlicensed site is returned unreviewed.

Identifying that Canadian partner is not a quick task. Licensed site holders have their own capacity constraints, due diligence processes, and acceptance criteria. And their GMP status must remain current for the lifetime of your product licence. If a partner site’s licence lapses or is suspended after your product licence is issued, your ability to continue distributing in Canada is directly affected. Build this into your supply chain planning early — not as an afterthought during submission preparation.

Five Steps European Brands Should Complete Before Filing an NPN Application

The rejection reasons above are preventable. Here’s the pre-submission sequence we use when working with European brands on Canadian market entry:

1. Run a compendial eligibility check. Before assembling your dossier, determine whether your product and proposed claims are covered by an existing NHPD product monograph. If they are, a compendial application pathway is faster, subject to lower evidentiary standards, and far more predictable. If they’re not, you need to plan for a non-compendial pathway and set realistic timeline expectations — 2 to 3 years is not unusual.

2. Audit your evidence file against NHPD standards, not EFSA. Review your existing evidence for the gaps NHPD reviewers flag most consistently: missing Latin binomial identification for botanical ingredients, traditional use evidence that doesn’t map precisely to your proposed form and dose, and preclinical studies submitted as primary support for a non-traditional claim. Identify and commission gap-filling studies before you submit, not after a Notice of Deficiency forces your hand.

3. Identify and contract a licensed Canadian site. Search Health Canada’s publicly available licensed site database, verify your candidate partner’s current licence status, and execute a formal commercial agreement before initiating your product licence application. Budget a minimum of 4 to 8 weeks for a partner’s own onboarding process — and treat your partner’s continued GMP compliance as an ongoing supply chain risk to monitor.

4. Develop your bilingual label in compliance with Part 5. This means complete English and French text for all mandatory fields, pre-populated with your proposed product licence terms. Have the label artwork reviewed by a Canadian regulatory consultant before submission. Post-submission label revisions are common, but catching bilingualism errors and missing mandatory fields early eliminates avoidable round-trips.

5. Pre-screen your complete application against NHPD’s published completeness checklist. Health Canada publishes guidance on what a complete product licence application must contain. A submission that fails the completeness screening is returned without entering substantive review — which means you lose weeks or months before your review clock even starts. A systematic completeness check against the guidance takes a few hours and can prevent a multi-month delay.

Canada’s natural health product market is worth approximately CAD $4.3 billion annually, and it continues to grow. The regulatory pathway is demanding — but it’s structured, it’s documented, and it’s navigable once you stop treating it as a variation on the EU system you already know. Build your dossier for Health Canada, not for EFSA, and most of the common rejection reasons disappear before submission day arrives.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about Health Canada NHPD compliance and Canadian market entry. Contact us

Related from our network

• Androxa — NHP Testing and Health Canada Compliance Support — Canadian laboratory testing services for natural health product brands navigating the NHPD licensing process.
• Qalitex Laboratories — ISO 17025-Accredited Ingredient and Finished Product Testing — US-based ISO 17025 laboratory providing identity, potency, and contaminant testing for supplement ingredients and finished NHP formulations.